

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1450 Alexandria, Virgiria 22313-1450 www.uspio.gov

07/28/2008

ELECTRONIC

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/965,610	09/26/2001	Adam S. Cantor	56032US022	8132	
32692 3M INNOVAT	7590 07/28/200	EXAM	EXAMINER		
PO BOX 3342	7	GHALI, ISIS A D			
ST. PAUL, MI	N 55133-3427	ART UNIT	PAPER NUMBER		
			1611		
			NOTIFICATION DATE	DELIVERY MODE	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

LegalUSDocketing@mmm.com LegalDocketing@mmm.com

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
09/965,610	CANTOR ET AL.	
Examiner	Art Unit	
Isis A. Ghali	1611	

	Isis A. Ghali	1611				
The MAILING DATE of this communication appe	ars on the cover sheet with the	correspondence add	ress			
THE REPLY FILED 24 June 2008 FAILS TO PLACE THIS APP	LICATION IN CONDITION FOR A	LLOWANCE.				
 The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following i application in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods: 	the same day as filing a Notice of eplies: (1) an amendment, affidavi al (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request			
perious: a) The period for reply expiresmonths from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whicheve no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: (fb ox 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHENT HE FIRST REPLY WAS FILED V						
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f		TINOTINETET WASTI	LD WITHIN TWO			
Extensions of time may be obtained under 37 CFR 1.136(a). The date whave been filled is the date for purposes of determining the period of a valued or 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earmed patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL.	ension and the corresponding amount nortened statutory period for reply origi	of the fee. The appropria nally set in the final Offic	ite extension fee e action; or (2) as			
 The Notice of Appeal was filed on <u>06/24/2008</u>. A brief in c date of filing the Notice of Appeal (37 CFR 41.37(a)), or an Since a Notice of Appeal has been filed, any reply must be AMENDMENTS 	y extension thereof (37 CFR 41.3)	7(e)), to avoid dismiss	al of the appeal			
3. The proposed amendment(s) filed after a final rejection, b	ut prior to the date of filing a brief,	will not be entered be	cause			
(a) They raise new issues that would require further cor	sideration and/or search (see NO	ΓE below);				
(b) They raise the issue of new matter (see NOTE below						
(c) They are not deemed to place the application in bett appeal; and/or	er form for appeal by materially re-	ducing or simplifying th	ne issues for			
(d) They present additional claims without canceling a c	orresponding number of finally reje	ected claims.				
NOTE: (See 37 CFR 1.116 and 41.33(a)).						
4. The amendments are not in compliance with 37 CFR 1.12	1. See attached Notice of Non-Co	mpliant Amendment (F	PTOL-324).			
5. Applicant's reply has overcome the following rejection(s):						
Newly proposed or amended claim(s) would be all non-allowable claim(s).	owable if submitted in a separate,	timely filed amendmer	t canceling the			
7. For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows:		l be entered and an ex	planation of			
Claim(s) allowed:						
Claim(s) objected to:						
Claim(s) rejected: <u>1-9,16-18,28-31,35-37,39-47 and 52-54</u> Claim(s) withdrawn from consideration: <u>48-51 and 55-91</u> .	•					
AFFIDAVIT OR OTHER EVIDENCE						
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 						
The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary	ercome <u>all</u> rejections under appea	al and/or appellant fails	to provide a			
 The affidavit or other evidence is entered. An explanation 	of the status of the claims after e	ntry is below or attache	ed.			
REQUEST FOR RECONSIDERATION/OTHER						
 The request for reconsideration has been considered but <u>See Continuation Sheet.</u> 	does NOT place the application in	condition for allowan	ce because:			
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s)					
13. Other:						
	/Isis A Ghali/					
	Primary Examiner, Art U	Init 1611				
	Zammor, rate					

Continuation of 11, does NOT place the application in condition for allowance because:

Claims have not amended and applicants repeat the same arguments regarding WO '229 and US '849, therefore, the examiner maintains her position as previously presented by the final office action. Further applicants argue that Roy et al. teach the same copolymer claimed by applicants and shows that not all the fentany is dissolved as required by the present claims. In response to this argument, it is argued that the copolymer disclosed by Roy et al. comprises copolymer containing 72% 2-ethylhexyl acrylate and 28% vinyl acetate, and the instantly claimed copolymer comprises about 52% to about 60% isocotoly acrylate, about 55% to about 40% 2-hydroxyad acrylate, about 1% to about 4% macromonomer, and 0% to about 10% vinyl acetate by weight. Therefore, the claimed polymer is totally different from the copolymer disclosed by Roy et al., therefore, does not have the same solubility to fentanyl.